相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice
Shelley J. Edmunds et al.
DIABETOLOGIA (2019)
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Antonino Di Pino et al.
ENDOCRINE REVIEWS (2019)
ComBATing aging-does increased brown adipose tissue activity confer longevity?
Justin Darcy et al.
GEROSCIENCE (2019)
Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
Karin Kornmueller et al.
MOLECULES (2019)
Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation
Tessa J. Barrett et al.
CIRCULATION (2019)
Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells
Enming Zhang et al.
CELL METABOLISM (2019)
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2019)
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
Andreas Gille et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
An Adipose Tissue Atlas: An Image-Guided Identification of Human-like BAT and Beige Depots in Rodents
Fang Zhang et al.
CELL METABOLISM (2018)
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial A Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA CARDIOLOGY (2018)
Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization
Jie Tang et al.
JOURNAL OF LIPID RESEARCH (2017)
Targeting white, brown and perivascular adipose tissue in atherosclerosis development
Andrea D. van Dam et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
Richard L. Dunbar et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM
Stephen C. Murray et al.
BIOPHYSICAL JOURNAL (2016)
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
C. Michael Gibson et al.
CIRCULATION (2016)
Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal
Joan Domingo-Espin et al.
DIABETES (2016)
In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes
Blake J. Cochran et al.
DIABETOLOGIA (2016)
Targeting and therapeutic peptides in nanomedicine for atherosclerosis
Eun Ji Chung
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux
David Meriwether et al.
JOURNAL OF LIPID RESEARCH (2016)
Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications
Jens B. Simonsen
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Microfluidics-mediated assembly of functional nanoparticles for cancer-related pharmaceutical applications
Qiang Feng et al.
NANOSCALE (2016)
Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease
Cheng-Gang Zhu et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development
Jimmy F. P. Berbee et al.
NATURE COMMUNICATIONS (2015)
It's Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
Gunther Marsche
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
Pierluigi Tricoci et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Jean-Claude Tardif et al.
EUROPEAN HEART JOURNAL (2014)
A Multiple Ascending Dose Study of CSL112, an Infused Formulation of ApoA-I
Rachael Easton et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Human disorders of leptin action
I. Sadaf Farooqi et al.
JOURNAL OF ENDOCRINOLOGY (2014)
HDL-targeted therapies: progress, failures and future
Bronwyn A. Kingwell et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation
Raphael Duivenvoorden et al.
NATURE COMMUNICATIONS (2014)
Single Step Reconstitution of Multifunctional High-Density Lipoprotein-Derived Nanomaterials Using Microfluidics
YongTae Kim et al.
ACS NANO (2013)
Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
Jonathan Dalla-Riva et al.
JOURNAL OF LIPID RESEARCH (2013)
Mimicry of High-Density Lipoprotein: Functional Peptide-Lipid Nanoparticles Based on Multivalent Peptide Constructs
Yannan Zhao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
The emerging role of HDL in glucose metabolism
Brian G. Drew et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel HDL-based therapeutic agents
Tisha R. Joy
PHARMACOLOGY & THERAPEUTICS (2012)
Fluid phase lipid areas and bilayer thicknesses of commonly used phosphatidylcholines as a function of temperature
Norbert Kucerka et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2011)
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Karin E. Bornfeldt et al.
CELL METABOLISM (2011)
4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice
Geoffrey D. Wool et al.
FASEB JOURNAL (2011)
Apolipoprotein A-I Mimetic Peptide L-4F Prevents Myocardial and Coronary Dysfunction in Diabetic Mice
C. Vecoli et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy
Lei Zhang et al.
JOURNAL OF LIPID RESEARCH (2011)
Biological activities of HDL subpopulations and their relevance to cardiovascular disease
Laurent Camont et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Apolipoprotein A-I Mimetic Peptides A Potential New Therapy for the Prevention of Atherosclerosis
Courtney B. Sherman et al.
CARDIOLOGY IN REVIEW (2010)
High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders
Sophie Van Linthout et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Menno Vergeer et al.
JOURNAL OF LIPID RESEARCH (2010)
Proteins Deleterious on Overexpression Are Associated with High Intrinsic Disorder, Specific Interaction Domains, and Low Abundance
Liang Ma et al.
JOURNAL OF PROTEOME RESEARCH (2010)
The promise of apolipoprotein A-I mimetics
Armando J. Mendez
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Brian G. Drew et al.
CIRCULATION (2009)
Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action
Godfrey S. Getz et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes
Sanjay Patel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Apolipoprotein A- I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties
Geoffrey D. Wool et al.
JOURNAL OF LIPID RESEARCH (2008)
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I
Brian J. Van Lenten et al.
JOURNAL OF LIPID RESEARCH (2008)
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
LeAnne T. Bloedon et al.
JOURNAL OF LIPID RESEARCH (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits
Brian J. Van Lenten et al.
JOURNAL OF LIPID RESEARCH (2007)
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis -: A randomized controlled trial
Jean-Claude Tardif et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Apolipoprotein A-I mimetic peptides
M Navab et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice
M Navab et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes
AL Kruger et al.
CIRCULATION (2005)
Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells
A Merglen et al.
ENDOCRINOLOGY (2004)
Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice
XJ Li et al.
CIRCULATION (2004)
Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice
M Navab et al.
CIRCULATION (2004)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease
JS Ou et al.
CIRCULATION (2003)
Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
M Navab et al.
CIRCULATION (2002)
分享论文
